Oncolytics Biotech Inc. progresses with pelareorep, showing a 33% response in relapsed anal carcinoma and exploring applications in metastatic pancreatic cancer, supported by a $5 million grant. The company faces…
Yubo International Biotech Ltd faces significant financial challenges, reporting zero revenue in Q1 2025, but remains committed to long-term growth. Operating primarily in China under VIE Yubo Beijing, the company…
Krystal Biotech is pioneering treatments for rare skin disorders using an HSV-1-based gene therapy platform. The company's vectors, including KB111 and KB112, effectively target skin keratinocytes with minimal toxicity. Significant…
AI's growth is driving massive energy consumption, with data centers consuming vast amounts of electricity akin to small towns. Current energy infrastructure struggles to keep pace with AI's escalating demands,…
Investors are increasingly interested in companies like Galmed Pharmaceuticals, Protagenic Therapeutics, and Hepion Pharmaceuticals for their innovative approaches in biotech. Galmed Pharmaceuticals is developing Aramchol for liver and fibro-inflammatory diseases,…
Elizabeth Holmes, former CEO of Theranos, remains influential in tech, advising Haemanthus from prison. Haemanthus, led by Billy Evans, aims to innovate medical testing using AI and Raman spectroscopy. Evans…
Insitro is downsizing its workforce by 22%, reflecting broader industry challenges in biotech fundraising. Led by Daphne Koller, Insitro combines machine learning with drug discovery, serving as an innovation leader.…
Shanghai Henlius Biotech is driving a quiet revolution in biotechnology from its base in Shanghai. The company recently held an Annual General Meeting, where all resolutions received strong shareholder approval,…
President Trump's executive order on drug pricing fuels debate, potentially reshaping U.S. healthcare economics and impacting the biotech industry. The directive proposes significant cuts in Medicaid drug reimbursements, posing a…
Swiss biotech sector shows resilience and innovation amidst a challenging global economy, with a significant rise in R&D investment in 2024. In 2025, the Swiss Biotech Report reveals SFr2.6 billion…